General Information of This Peptide
Peptide ID
PEP00113
Peptide Name
Ac-NleEHfRWGK-NH<sub>2</sub>
Structure
Sequence
NleEHfRWGK-NH2
Peptide Type
Linear
Receptor Name
Melanocyte-stimulating hormone receptor (MC1R)
 Receptor Info 
PDC Transmembrane Types Cell targeting peptides (CTPs)
Formula
C51H73N15O11
Isosmiles
[H]NCCCC[C@H](NC(=O)CNC(=O)[C@H](Cc1cn([H])c2ccccc12)NC(=O)[C@H](CCC/N=C(\N)N[H])NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cn([H])cn1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCCC)C(=O)O
InChI
InChI=1S/C51H73N15O11/c1-2-3-15-34(53)44(70)62-37(19-20-43(68)69)47(73)66-41(25-32-27-56-29-60-32)49(75)64-39(23-30-12-5-4-6-13-30)48(74)63-36(18-11-22-57-51(54)55)46(72)65-40(24-31-26-58-35-16-8-7-14-33(31)35)45(71)59-28-42(67)61-38(50(76)77)17-9-10-21-52/h4-8,12-14,16,26-27,29,34,36-41,58H,2-3,9-11,15,17-25,28,52-53H2,1H3,(H,56,60)(H,59,71)(H,61,67)(H,62,70)(H,63,74)(H,64,75)(H,65,72)(H,66,73)(H,68,69)(H,76,77)(H4,54,55,57)/t34-,36-,37-,38-,39-,40-,41-/m0/s1
InChIKey
OPPASPHVSXCYPC-FTZOFIEWSA-N
Pharmaceutical Properties
Molecule Weight
1072.239
Polar area
439.21
Complexity
1071.561398
xlogp Value
-1.4066
Heavy Count
77
Rot Bonds
36
Hbond acc
13
Hbond Donor
15
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
Ac-NleEHfRWGK(Dau=Aoa)-NH2 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.06 ± 0.10 µM
Administration Time 24 h
Evaluation Method MTT assay
MOA of PDC
In this study, the native sequence of -MSH was used, in which Met was replaced by Nle (SYSNleEHFRWGKPV). Daunomycin was attached to the amino functional groups via non-cleavable oxime linkage. These types of conjugates have many excellent properties to study and compare the bioactivity of the compounds. One of the developed conjugates contained drug molecules on both conjugation site (N-terminal and the side chain of Lys). The two additional conjugates were modified by the drug, either on theN-terminus or on the Lys side chain. The in vitro cytostatic effect on mouse melanoma cells did not show any significant differences among them. However, results indicated that the conjugates with Dau on the side chain of Lys could enter the cells more rapidly and efficiently. In contrast, the in vivo tumor growth inhibition was the most pronounced in the case of Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2(Conj2). It is worth mentioning that the dose was normalized to Dau content, thus the injected dose ofConj3was half that ofConj 2. Nevertheless,Conj2, with one molecule of the drug, might be superior to the conjugate containing two molecules of daunomycin. The higher tumor growth inhibition effect ofConj2overConj1where the Dau is connected to theN-terminus, confirms our previous results with Dau-GnRH-III (Glp-His-Trp-Lys(Bu)-His-Asp-Trp-Lys(Dau=Aoa)-Pro-Gly-NH2), suggesting that H-Lys(Dau=Aoa)-OH can release easily from this position by the dipeptidyl-peptidase activity of cathepsin B.

   Click to Show/Hide
Description
The in vitro cytostatic effects of Dau--MSH conjugates were compared with the PrestoBlue assay, which has a higher specificity and efficacy that of the previously used MTT assay, using the same six human melanoma cell lines used in the real-time qPCR assay. According to our results, free daunomycin exhibited the lowest IC50 values, and therefore the highest cytostatic effect, due to the fact that free daunomycin passively diffuses into cells. Our Dau--MSH conjugates showed similar trends in the effectiveness of the tested cell lines. Conj2 and Conj4 resulted in IC50 values in the low uM range. A calculation of the targeting indices showed that compound Conj2 had an over 2-times higher targeting efficiency in most cell lines compared to the A2058 cell line. Interestingly, WM983A showed the lowest TI among the high-MC1R-expressing cell lines compared to A2058, and WM983B exhibited high TI regardless of the relatively low MC1R expression on the mRNA level. In the case of Conj4, the treatment resulted in the highest TIs with OCM-1 and WM983B cell lines.

   Click to Show/Hide
In Vitro Model Melanoma SK-MEL-202 cell CVCL_6106
Experiment 2 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
7.15 ± 0.07 µM
Administration Time 24 h
Evaluation Method MTT assay
MOA of PDC
In this study, the native sequence of -MSH was used, in which Met was replaced by Nle (SYSNleEHFRWGKPV). Daunomycin was attached to the amino functional groups via non-cleavable oxime linkage. These types of conjugates have many excellent properties to study and compare the bioactivity of the compounds. One of the developed conjugates contained drug molecules on both conjugation site (N-terminal and the side chain of Lys). The two additional conjugates were modified by the drug, either on theN-terminus or on the Lys side chain. The in vitro cytostatic effect on mouse melanoma cells did not show any significant differences among them. However, results indicated that the conjugates with Dau on the side chain of Lys could enter the cells more rapidly and efficiently. In contrast, the in vivo tumor growth inhibition was the most pronounced in the case of Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2(Conj2). It is worth mentioning that the dose was normalized to Dau content, thus the injected dose ofConj3was half that ofConj 2. Nevertheless,Conj2, with one molecule of the drug, might be superior to the conjugate containing two molecules of daunomycin. The higher tumor growth inhibition effect ofConj2overConj1where the Dau is connected to theN-terminus, confirms our previous results with Dau-GnRH-III (Glp-His-Trp-Lys(Bu)-His-Asp-Trp-Lys(Dau=Aoa)-Pro-Gly-NH2), suggesting that H-Lys(Dau=Aoa)-OH can release easily from this position by the dipeptidyl-peptidase activity of cathepsin B.

   Click to Show/Hide
Description
The in vitro cytostatic effects of Dau--MSH conjugates were compared with the PrestoBlue assay, which has a higher specificity and efficacy that of the previously used MTT assay, using the same six human melanoma cell lines used in the real-time qPCR assay. According to our results, free daunomycin exhibited the lowest IC50 values, and therefore the highest cytostatic effect, due to the fact that free daunomycin passively diffuses into cells. Our Dau--MSH conjugates showed similar trends in the effectiveness of the tested cell lines. Conj2 and Conj4 resulted in IC50 values in the low uM range. A calculation of the targeting indices showed that compound Conj2 had an over 2-times higher targeting efficiency in most cell lines compared to the A2058 cell line. Interestingly, WM983A showed the lowest TI among the high-MC1R-expressing cell lines compared to A2058, and WM983B exhibited high TI regardless of the relatively low MC1R expression on the mRNA level. In the case of Conj4, the treatment resulted in the highest TIs with OCM-1 and WM983B cell lines.

   Click to Show/Hide
In Vitro Model Melanoma A2058 cell CVCL_1059
Experiment 3 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
10.18 ± 0.06 µM
Administration Time 24 h
Evaluation Method MTT assay
MOA of PDC
In this study, the native sequence of -MSH was used, in which Met was replaced by Nle (SYSNleEHFRWGKPV). Daunomycin was attached to the amino functional groups via non-cleavable oxime linkage. These types of conjugates have many excellent properties to study and compare the bioactivity of the compounds. One of the developed conjugates contained drug molecules on both conjugation site (N-terminal and the side chain of Lys). The two additional conjugates were modified by the drug, either on theN-terminus or on the Lys side chain. The in vitro cytostatic effect on mouse melanoma cells did not show any significant differences among them. However, results indicated that the conjugates with Dau on the side chain of Lys could enter the cells more rapidly and efficiently. In contrast, the in vivo tumor growth inhibition was the most pronounced in the case of Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2(Conj2). It is worth mentioning that the dose was normalized to Dau content, thus the injected dose ofConj3was half that ofConj 2. Nevertheless,Conj2, with one molecule of the drug, might be superior to the conjugate containing two molecules of daunomycin. The higher tumor growth inhibition effect ofConj2overConj1where the Dau is connected to theN-terminus, confirms our previous results with Dau-GnRH-III (Glp-His-Trp-Lys(Bu)-His-Asp-Trp-Lys(Dau=Aoa)-Pro-Gly-NH2), suggesting that H-Lys(Dau=Aoa)-OH can release easily from this position by the dipeptidyl-peptidase activity of cathepsin B.

   Click to Show/Hide
Description
The in vitro cytostatic effects of Dau--MSH conjugates were compared with the PrestoBlue assay, which has a higher specificity and efficacy that of the previously used MTT assay, using the same six human melanoma cell lines used in the real-time qPCR assay. According to our results, free daunomycin exhibited the lowest IC50 values, and therefore the highest cytostatic effect, due to the fact that free daunomycin passively diffuses into cells. Our Dau--MSH conjugates showed similar trends in the effectiveness of the tested cell lines. Conj2 and Conj4 resulted in IC50 values in the low uM range. A calculation of the targeting indices showed that compound Conj2 had an over 2-times higher targeting efficiency in most cell lines compared to the A2058 cell line. Interestingly, WM983A showed the lowest TI among the high-MC1R-expressing cell lines compared to A2058, and WM983B exhibited high TI regardless of the relatively low MC1R expression on the mRNA level. In the case of Conj4, the treatment resulted in the highest TIs with OCM-1 and WM983B cell lines.

   Click to Show/Hide
In Vitro Model Melanoma WM983B cell CVCL_6809
Experiment 4 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
13.50 ± 0.06 µM
Administration Time 24 h
Evaluation Method MTT assay
MOA of PDC
In this study, the native sequence of -MSH was used, in which Met was replaced by Nle (SYSNleEHFRWGKPV). Daunomycin was attached to the amino functional groups via non-cleavable oxime linkage. These types of conjugates have many excellent properties to study and compare the bioactivity of the compounds. One of the developed conjugates contained drug molecules on both conjugation site (N-terminal and the side chain of Lys). The two additional conjugates were modified by the drug, either on theN-terminus or on the Lys side chain. The in vitro cytostatic effect on mouse melanoma cells did not show any significant differences among them. However, results indicated that the conjugates with Dau on the side chain of Lys could enter the cells more rapidly and efficiently. In contrast, the in vivo tumor growth inhibition was the most pronounced in the case of Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2(Conj2). It is worth mentioning that the dose was normalized to Dau content, thus the injected dose ofConj3was half that ofConj 2. Nevertheless,Conj2, with one molecule of the drug, might be superior to the conjugate containing two molecules of daunomycin. The higher tumor growth inhibition effect ofConj2overConj1where the Dau is connected to theN-terminus, confirms our previous results with Dau-GnRH-III (Glp-His-Trp-Lys(Bu)-His-Asp-Trp-Lys(Dau=Aoa)-Pro-Gly-NH2), suggesting that H-Lys(Dau=Aoa)-OH can release easily from this position by the dipeptidyl-peptidase activity of cathepsin B.

   Click to Show/Hide
Description
The in vitro cytostatic effects of Dau--MSH conjugates were compared with the PrestoBlue assay, which has a higher specificity and efficacy that of the previously used MTT assay, using the same six human melanoma cell lines used in the real-time qPCR assay. According to our results, free daunomycin exhibited the lowest IC50 values, and therefore the highest cytostatic effect, due to the fact that free daunomycin passively diffuses into cells. Our Dau--MSH conjugates showed similar trends in the effectiveness of the tested cell lines. Conj2 and Conj4 resulted in IC50 values in the low uM range. A calculation of the targeting indices showed that compound Conj2 had an over 2-times higher targeting efficiency in most cell lines compared to the A2058 cell line. Interestingly, WM983A showed the lowest TI among the high-MC1R-expressing cell lines compared to A2058, and WM983B exhibited high TI regardless of the relatively low MC1R expression on the mRNA level. In the case of Conj4, the treatment resulted in the highest TIs with OCM-1 and WM983B cell lines.

   Click to Show/Hide
In Vitro Model Melanoma WM983A cell CVCL_6808
Experiment 5 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
25.47 ± 0.08 µM
Administration Time 24 h
Evaluation Method MTT assay
MOA of PDC
In this study, the native sequence of -MSH was used, in which Met was replaced by Nle (SYSNleEHFRWGKPV). Daunomycin was attached to the amino functional groups via non-cleavable oxime linkage. These types of conjugates have many excellent properties to study and compare the bioactivity of the compounds. One of the developed conjugates contained drug molecules on both conjugation site (N-terminal and the side chain of Lys). The two additional conjugates were modified by the drug, either on theN-terminus or on the Lys side chain. The in vitro cytostatic effect on mouse melanoma cells did not show any significant differences among them. However, results indicated that the conjugates with Dau on the side chain of Lys could enter the cells more rapidly and efficiently. In contrast, the in vivo tumor growth inhibition was the most pronounced in the case of Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2(Conj2). It is worth mentioning that the dose was normalized to Dau content, thus the injected dose ofConj3was half that ofConj 2. Nevertheless,Conj2, with one molecule of the drug, might be superior to the conjugate containing two molecules of daunomycin. The higher tumor growth inhibition effect ofConj2overConj1where the Dau is connected to theN-terminus, confirms our previous results with Dau-GnRH-III (Glp-His-Trp-Lys(Bu)-His-Asp-Trp-Lys(Dau=Aoa)-Pro-Gly-NH2), suggesting that H-Lys(Dau=Aoa)-OH can release easily from this position by the dipeptidyl-peptidase activity of cathepsin B.

   Click to Show/Hide
Description
The in vitro cytostatic effects of Dau--MSH conjugates were compared with the PrestoBlue assay, which has a higher specificity and efficacy that of the previously used MTT assay, using the same six human melanoma cell lines used in the real-time qPCR assay. According to our results, free daunomycin exhibited the lowest IC50 values, and therefore the highest cytostatic effect, due to the fact that free daunomycin passively diffuses into cells. Our Dau--MSH conjugates showed similar trends in the effectiveness of the tested cell lines. Conj2 and Conj4 resulted in IC50 values in the low uM range. A calculation of the targeting indices showed that compound Conj2 had an over 2-times higher targeting efficiency in most cell lines compared to the A2058 cell line. Interestingly, WM983A showed the lowest TI among the high-MC1R-expressing cell lines compared to A2058, and WM983B exhibited high TI regardless of the relatively low MC1R expression on the mRNA level. In the case of Conj4, the treatment resulted in the highest TIs with OCM-1 and WM983B cell lines.

   Click to Show/Hide
In Vitro Model Cutaneous melanoma OCM-3 cell CVCL_6937
Experiment 6 Reporting the Activity Data of This PDC [1]
Indication Melanoma
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
29.68 ± 0.06 µM
Administration Time 24 h
Evaluation Method MTT assay
MOA of PDC
In this study, the native sequence of -MSH was used, in which Met was replaced by Nle (SYSNleEHFRWGKPV). Daunomycin was attached to the amino functional groups via non-cleavable oxime linkage. These types of conjugates have many excellent properties to study and compare the bioactivity of the compounds. One of the developed conjugates contained drug molecules on both conjugation site (N-terminal and the side chain of Lys). The two additional conjugates were modified by the drug, either on theN-terminus or on the Lys side chain. The in vitro cytostatic effect on mouse melanoma cells did not show any significant differences among them. However, results indicated that the conjugates with Dau on the side chain of Lys could enter the cells more rapidly and efficiently. In contrast, the in vivo tumor growth inhibition was the most pronounced in the case of Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2(Conj2). It is worth mentioning that the dose was normalized to Dau content, thus the injected dose ofConj3was half that ofConj 2. Nevertheless,Conj2, with one molecule of the drug, might be superior to the conjugate containing two molecules of daunomycin. The higher tumor growth inhibition effect ofConj2overConj1where the Dau is connected to theN-terminus, confirms our previous results with Dau-GnRH-III (Glp-His-Trp-Lys(Bu)-His-Asp-Trp-Lys(Dau=Aoa)-Pro-Gly-NH2), suggesting that H-Lys(Dau=Aoa)-OH can release easily from this position by the dipeptidyl-peptidase activity of cathepsin B.

   Click to Show/Hide
Description
The in vitro cytostatic effects of Dau--MSH conjugates were compared with the PrestoBlue assay, which has a higher specificity and efficacy that of the previously used MTT assay, using the same six human melanoma cell lines used in the real-time qPCR assay. According to our results, free daunomycin exhibited the lowest IC50 values, and therefore the highest cytostatic effect, due to the fact that free daunomycin passively diffuses into cells. Our Dau--MSH conjugates showed similar trends in the effectiveness of the tested cell lines. Conj2 and Conj4 resulted in IC50 values in the low uM range. A calculation of the targeting indices showed that compound Conj2 had an over 2-times higher targeting efficiency in most cell lines compared to the A2058 cell line. Interestingly, WM983A showed the lowest TI among the high-MC1R-expressing cell lines compared to A2058, and WM983B exhibited high TI regardless of the relatively low MC1R expression on the mRNA level. In the case of Conj4, the treatment resulted in the highest TIs with OCM-1 and WM983B cell lines.

   Click to Show/Hide
In Vitro Model Amelanotic melanoma OCM-1 cell CVCL_6934
References
Ref 1 Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of -MSH-Peptide Conjugates. Int J Mol Sci. 2024 Jan 16;25(2):1095. doi: 10.3390/ijms25021095.